Led,
I often think that a reunification of Resverlogix and Zenith would be wise. Zenith was spun out in June 2013. At the time, it was a way to separate the apoAI/HDL/RVX-208/cardiovascular program and related BET inhibitor compounds from the rest of the BET platform technologies. These latter became Zenith with an initial focus on autoimmune and cancer. Part of this spin out was also the creation of royalty preferred shares that would provide future Rvx-208 royalties to Zenith. This spin out and royalty arrangement was done in part to prep Resverlogix and RVX-208 for sale on the expectation that Phase 2 ASSURE would have clear cut impressive out of the park results. As we know, RVX missed their primary endpoint.
Fast forward 3 years and now Resverlogix is almost a year into their Phase 3 BETonMACE, is almost done with a Phase 1 Renal trial, and has complement/orphan/alzheimer's trials in the works. Zenith has two prostate cancer Phase 1 trials ongoing as well. So we have two similar BET inhibitor based companies, both highly active in clinical trials and both with over a thousand compounds in each of their libraries. Both have the same CEO and other overlap in their management and board of directors.
A reunification sounds like a reasonable speculation to me.
BearDownAZ
